当前位置: X-MOL首页全球导师 国内导师 › 夏宁邵
扫描左侧二维码
使用公众号菜单
手机上轻松查询100,000+导师

个人简介

1995年至2002年,厦门大学生命科学学院,副教授 2002年至今,厦门大学生命科学学院,教授、博导 2005年至今,国家传染病诊断试剂与疫苗工程技术研究中心主任 2011年至今,厦门大学公共卫生学院,院长

研究领域

传染病防控的基础研究、应用基础研究、转化医学研究,诊断试剂、疫苗、抗体研发,涉及病毒性肝炎、艾滋病、流感、手足口病、结核、人乳头瘤病毒相关疾病等。

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Xu LF#, Zheng QB#, Zhu R#, Yin ZC#, Yu H#, Lin Y, Wu YY, He MZ, Huang Y, Jiang YC, Sun H, Zha ZH, Yang HW, Huang QZ, Zhang DQ, Chen ZQ, Ye XZ, Han JL, Yang LS, Liu C, Que YQ, Fang MJ, Gu Y, Zhang J, Luo W, Zhou ZH*, Li SW*, Cheng T*, Xia NS*. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host & Microbe. 2021; 29: 1-15. (IF=15.923) He MZ#, Xu LF#, Zheng QB#, Zhu R#, Yin ZC#, Zha ZH, Lin Y, Yang LS, Huang Y, Ye XZ, Li SX, Hou WH, Wu YT, Han JL, Liu DX, Li ZK, Chen ZQ, Yu H, Que YQ, Wang YB, Yan XD, Zhang J, Gu Y, Zhou ZH*, Cheng T*, Li SW*, Xia NS*. Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16. Cell Host & Microbe. 2020; 27(2): 249-261. (IF=15.923) Wang W#, Zheng QB#, Pan DQ#, Yu H#, Fu WK, Liu J, He MZ, Zhu R, Cai YZ, Huang Y, Zha ZH, Chen ZQ, Ye XZ, Han JL, Que YQ, Wu T, Zhang J, Li SW*, Zhu H*, Zhou ZH*, Cheng T*, Xia NS*. Near-atomic cryo-electron microscopy structures of varicella-zoster virus capsids. Nature Microbiology. 2020; 5: 1542-1552. (IF=15.540) Wang DN#, Liu XL#, Wei MX#, Qian CY, Song S, Chen J, Wang ZP, Xu Q, Yang YR, He MZ, Chi X, Huang SW, Li TT, Kong ZB, Zheng QB, Yu H, Wang YB, Zhao QJ, Zhang J, Xia NS*, Gu Y*, Li SW*. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nature Communications. 2020; 11(1): 2841. (IF=12.121) Wen GP#, He LL#, Tang ZM#, Wang SL#, Zhang X, Chen YZ, Lin XH, Liu C, Chen JX, Ying D, Chen ZH, Wang YB, Luo WX, Huang SJ, Li SW, Zhang J, Zheng ZZ*, Zhu J*, Xia NS*. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nature Communications. 2020; 11(1): 3971. (IF=12.121) Zhang YL#, Wang SJ#, Wu YT#, Hou WH#, Yuan LZ#, Sheng CG#, Wang J, Ye JH, Zheng QB, Ma J, Xu JJ, Wei M, Li ZL, Nian S, Xiong HL, Zhang L, Shi Y, Fu BR, Cao JL, Yang CL, Li ZY, Yang T, Liu L, Yu H, Hu JD, Ge SX, Chen YX, Zhang TY, Zhang J, Cheng T*, Yuan Q*, Xia NS*. Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods. 2020; 5(2): 2001031. (IF=12.130) Zhang TY#, Chen HY#, Cao JL#, Xiong HL, Mo XB, Li TL, Kang XZ, Zhao JH, Yin B, Zhao X, Huang CH, Yuan Q*, Xue D*, Xia NS*, Yuan YA. Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction. Nature Communications. 2019; 10(1): 3192. (IF=12.121) Liu X#, Liu C#, Zheng ZZ#, Chen SY, Pang X, Xiang XC, Tang JX, Ren E, Chen YZ, You M, Wang XY, Chen XY, Luo WX*, Liu G*, Xia NS*. Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy. Advanced Materials. 2019; 31(17): e1808294. (IF=27.398) Yuan LZ#, Jiang J#, Liu X#, Zhang YL, Zhang L, Xin JJ, Wu K, Li XL, Cao JL, Guo XR, Shi DY, Li J, Jiang LY, Sun SW, Wang TY, Hou WH, Zhang TY, Zhu H, Zhang J, Yuan Q, Cheng T*, Li J*, Xia NS*. HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation. Gut. 2019; 68(11): 2044-2056. (IF=19.819) Zhang TY#, Guo XR#, Wu YT#, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Ge SX, Chen PJ, Zhang J*, Yuan Q*, Xia NS*. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut. 2020; 69(2): 343-354. (IF=19.819) Qiao YL#*, Wu T#, Li RC#, Hu YM#, Wei LH#, Li CG#, Chen W#, Huang SJ, Zhao FH, Li MQ, Pan QJ, Zhang X, Li Q, Hong Y, Zhao C, Zhang WH, Li YP, Chu K, Li M, Jiang YF, Li J, Zhao H, Lin ZJ, Cui XL, Liu WY, Li CH, Guo DP, Ke LD, Wu X, Tang J, Gao GQ, Li BY, Zhao B, Zheng FX, Dai CH, Guo M, Zhao J, Su YY, Wang JZ, Zhu FC, Li SW, Pan HR, Li YM, Zhang J*, Xia NS*. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial. Journal of the National Cancer Institute. 2020; 112(2): 145-153. (IF=11.577) Zheng QB,# Jiang J#, He MZ#, Zheng ZZ#, Yu H, Li TT, Xue WH, Tang ZM, Ying D, Li ZK, Song S, Liu XL, Wang KH, Zhang ZQ, Wang DN, Wang YB, Yan XD, Zhao QJ, Zhang J, Gu Y*, Li SW*, Xia NS*. Viral neutralization by antibody-imposed physical disruption. Proceedings of the National Academy of Sciences of the United States of America. 2019; 116(52): 26933-26940. (IF=9.412) Zheng QB#, Zhu R#, Xu LF#, He MZ#, Yan XD#, Liu DX, Yin ZC, Wu YT, Li YC, Yang LS, Hou WH, Li SX, Li ZZ, Chen ZQ, Li ZH, Yu H, Gu Y, Zhang J, Baker TS, Zhou ZH, Graham BS*, Cheng T*, Li SW*, Xia NS*. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nature Microbiology. 2019; 4(1): 124-133. (IF=15.540) Li ZH#, Song S#, He MZ#, Wang DN, Shi JJ, Liu XL, Li YB, Chi X, Wei SP, Yang YR, Wang ZP, Li JJ, Qian HL, Yu H, Zheng QB, Yan XD, Zhao QJ, Zhang J, Gu Y*, Li SW*, Xia NS*. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nature Communications. 2018; 9: 5360. (IF=12.121) Zhu R#, Xu LF#, Zheng QB#, Cui YX#, Li SW#, He MZ, Yin ZC, Liu DX, Li SX, Li ZZ, Chen ZQ, Yu H, Que YQ, Liu C, Kong Z, Zhang JB, Baker TS, Yan XD*, Zhou ZH*, Cheng T*, Xia NS*. Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science Advances. 2018; 4(9): eaat7459. (IF=13.117) Shen CG, Chen JY, Li R, Zhang MY, Wang GS, Stegalkina S, Zhang LM, Chen J, Cao JL, Bi XJ, Anderson SF, Alefantis T, Zhang MW, Cai XY, Yang KY, Zheng QB, Fang MJ, Yu H, Luo WX, Zheng ZZ, Yuan Q, Zhang J, Shih JWK, Kleanthous H, Chen HL, Chen YX*, Xia NS*. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science Translational Medicine. 2017; 9(412): eaam5752. (IF=16.304) Xu LF, Zheng QB, Li SW, He MZ, Wu YT, Li YC, Zhu R, Yu H, Hong QY, Jiang J, Li ZZ, Li SX, Zhao H, Yang LS, Hou WH, Wang W, Ye XZ, Zhang J, Baker TS, Cheng T*, Zhou ZH, Yan XD*, Xia NS*. Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nature Communications. 2017; 8: 505. (IF=12.121) Tian DY, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS*, McLellan JS*, Graham BS*. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nature Communications. 2017; 8: 1877. (IF=12.121) Zhang TY, Yuan Q*, Zhao JH, Zhang YL, Yuan LZ, Lan Y, Lo YC, Sun CP, Wu CR, Zhang JF, Zhang Y, Cao JL, Guo XR, Liu X, Mo XB, Luo WX, Cheng T, Chen YX, Tao MH, Shih JWK, Zhao QJ, Zhang J, Chen PJ, Yuan YA*, Xia NS*. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut. 2016; 65(4): 658-671. (IF=19.819) Fan R, Sun J, Yuan Q, Xie Q, Bai XF, Ning Q, Cheng J, Yu YY, Niu JQ, Shi GF, Wang H, Tan DM, Wan MB, Chen SJ, Xu M, Chen XY, Tang H, Sheng JF, Lu FM, Jia JD, Zhuang H, Xia NS*, Hou JL*, Chronic Hepatitis B SC. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016; 65(2): 313-320. (IF=19.819)

推荐链接
down
wechat
bug